Specific recommendations for implantation of each prosthesis , taking into consideration the presence of pre-existent conduction abnormalities and anatomical factors , may be needed to reduce the risk of PPI
Aims The incidence of new-onset conduction abnormalities requiring permanent pacemaker implantation ( PPI ) after transcatheter aortic valve implantation ( TAVI ) with new-generation prostheses remains debated .
This systematic review analyses the incidence of PPI after TAVI  with new-generation devices and evaluates the electrical , anatomical , and procedural factors associated with PPI .
In addition , the incidence of PPI after  TAVI with early generation prostheses was review ed for comparison .
The JUPITER registry: 1-year results of transapical aortic valve implantation using a second-generation transcatheter heart valve in patients with aortic stenosis.
OBJECTIVES Transcatheter aortic valve replacement ( TAVR ) is an established therapy for patients with aortic stenosis ( AS ) at high surgical risk .  The JenaValve ™ is a second-generation , self-exp and ing transcatheter heart valve ( THV ) , implanted through transapical access ( TA ) . During stent deployment , a specific ' clipping-mechanism ' engages native aortic valve cusps for fixation . We present 1-year outcomes of the JUPITER registry , a post-market registry of the JenaValve for TA-TAVR . METHODS The JUPITER registry is a prospect i ve , multicentre , uncontrolled and observational European study to evaluate the long-term safety and effectiveness of the Conformité Européenne-marked JenaValve THV . A total of 180 patients with AS were enrolled between 2012 and 2014 . End-points were adjudicated in accordance with the valve academic research consortium document no. 1 definitions . RESULTS The mean age was 80.4 ± 5.9 years and the mean logistic  European system for cardiac operative risk evaluation I 21.2 ± 14.7 % . The procedure was successful in 95.0 % ( 171/180 ) , implantation of a second THV ( valve-in-valve ) was performed in 2.2 % ( 4/180 ) and conversion to surgical aortic valve replacement ( SAVR ) was necessary in 2.8 % ( 5/180 ) . No annular rupture or coronary ostia obstruction occurred . Two patients required SAVR after the day of index procedure ( 1.1 % ) . All-cause mortality at 30 days was 11.1 % ( 20/180 ) , being cardiovascular in 7.2 % ( 13/180 ) . A major stroke occurred in 1.1 % ( 2/180 ) at 30 days , no additional major strokes were observed during 1 year . All-cause mortality after 30 days was 13.1 % ( 21/160 ) and combined efficacy at 1 year was 80.8 % ( 122/151 ) . At 1-year follow-up , no patient presented with more than moderate paravalvular leakage , while 2 patients ( 3.2 % ) showed moderate , 12 ( 19.0 % ) mild and 49 ( 82.4 % ) trace/none paravalvular regurgitation . CONCLUSIONS In a high-risk cohort of patients undergoing TA-TAVR  for AS , the use of the JenaValve THV is safe and effective . In patients at higher risk for coronary ostia obstruction , annular rupture or with limited aortic valve calcification , the JenaValve might be preferable for implantation due to its clipping-mechanism engaging native aortic valve cusps for fixation with reduced radial forces of the self-exp and ing stent
Specific recommendations for implantation of each prosthesis , taking into consideration the presence of pre-existent conduction abnormalities and anatomical factors , may be needed to reduce the risk of PPI
Aims The incidence of new-onset conduction abnormalities requiring permanent pacemaker implantation ( PPI ) after transcatheter aortic valve implantation ( TAVI ) with new-generation prostheses remains debated .
This systematic review analyses the incidence of PPI after TAVI  with new-generation devices and evaluates the electrical , anatomical , and procedural factors associated with PPI .
In addition , the incidence of PPI after  TAVI with early generation prostheses was review ed for comparison .